Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Q32 Bio Inc.

35 indications, side-by-side phase, drug & LoA

$12.64

+0.02 (+0.16%)

D 39Pipeline Score Fair Value Biotech · Commercial
Market Cap
98.35 M
EPS
2.67
P/E Ratio
2.18 $
Value Trade
6.46 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • R&D Expenses

    3.22 M

  • Operating CF

    -6.34 M

  • Total Assets

    63.67 M

  • Total Liabilities

    17.36 M

  • Equity

    46.31 M

  • D/E Ratio

    12,345

-5.69 %
Week
-10.77 %
1 Month
40.1 %
3 Month
200.52 %
6 Month
-94.93 %
5 Year
-98.6 %
All Time
Cash Data
Stable

  • Cash Position

    50.75 M

  • Monthly Burn

    2.11 M

  • Runway

    22.8 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 5, 2026
Overview
Volume
326.90 K
52 Week Range
1.35 - 8.05
% held by Insiders
55.48 %
% held by Institutions
57.48 %
Enterprise Value
61.24 M
Total Shares
14.61 M
Short %
11.41 %
Float Shares
5.55 M
Company Description
HQ: 830 WINTER STREET, WALTHAM, MA...
Employees:22
https://www.q32bio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2a topline data readout example
bempikibart alopecia areata
Phase 2a
—
Biologics
Dermatologic System
bempikibart alopecia areata
Phase 2a
—
Biologics
Dermatologic System
bempikibart alopecia areata
Phase 2a
—
Biologics
Dermatologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D39
Pipeline Score
$63M
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
2.2x
rNPV / MCap
Top 50%
Micro Cap
(rank 453 of 905)
Percentile Rank
Q32 Bio Inc. faces pipeline headwinds (39/100), with $896M risk-adjusted pipeline value, led by ADX-914 in Atopic Dermatitis (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
ADX-914
Small molecule		Atopic DermatitisPhase 2NCT0550902317% $748M ACTIVE NOT_RECRUITING 102 SLOW B (61) Dec 1, 2024MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
bempikibart
alopecia areata
Phase 2a
2025-08-06
bempikibart
alopecia areata
Phase 2a
2025-08-06
bempikibart
alopecia areata
Phase 2a
2025-08-06
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in QTTB
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
QTTB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QTTB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QTTB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
QTTB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
QTTB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Q32 Bio Inc. (QTTB) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How QTTB ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Alopecia #8 of 12 PHASE 2 bempikibart
PFE MANE ABBV
$10.76B 0.88 FOLLOWER
Atopic Dermatitis #18 of 25 PHASE 2 ADX-914
LLY ABBV PFE
$20.76B 0.92 FOLLOWER